In addition, our data warrant close monitoring of EBV‐seronegative patients with SD and of patients with persistent inflammation (high or increasing ferritin and/or IL‐18 levels) and therefore an increased risk for MAS development. The gene discussed is IL18; the disease is macrophage activation syndrome.